Mackenzie Financial
HTGM

Mackenzie Financial’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Mackenzie Financial’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-164
Closed -$80K – 875
2016
Q2 		$80K Buy
164
+2
+1% +$1.01K ﹤0.01% 910
2016
Q1 		$84K Hold
162
– – ﹤0.01% 791
2015
Q4 		$127K Hold
162
– – ﹤0.01% 797
2015
Q3 		$223K Buy
+162
New +$250K ﹤0.01% 765

Other funds holding HTGM

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Mackenzie Financial's HTGM Position: Q3 2016 in Review

Mackenzie Financial sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2016, closing a stake of 164 shares — an estimated $80K sold.

Mackenzie Financial first reported a position in HTGM in Q3 2015 and held it in 4 quarters. The position peaked at $223K in Q3 2015. 22 funds tracked by Wall St. Rank hold HTGM as of Q3 2016.

  • Mackenzie Financial reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • Mackenzie Financial sold 164 HTG Molecular Diagnostics, Inc. Common Stock shares in Q3 2016, an estimated $80K.
  • Mackenzie Financial first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2015 and held it in 4 quarters.
  • Mackenzie Financial's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $223K in Q3 2015.
  • 22 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2016.

Based on Mackenzie Financial's 13F filing for Q3 2016, filed 15 Nov 2016.